Trial · NCT02139046
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | Placebo | 0.3 | percentage of participants | ||
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | Febuxostat IR 40 mg | 15.7 | percentage of participants | ||
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | Febuxostat XR 40 mg | 25.9 | percentage of participants | ||
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | Febuxostat IR 80 mg | 42.6 | percentage of participants | ||
| Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 | Febuxostat XR 80 mg | 50.1 | percentage of participants | ||
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | Placebo | 20.7 | percentage of participants | ||
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | Febuxostat IR 40 mg | 21.0 | percentage of participants | ||
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | Febuxostat XR 40 mg | 22.8 | percentage of participants | ||
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | Febuxostat IR 80 mg | 27.2 | percentage of participants | ||
| Percentage of Participants With at Least One Gout Flare Requiring Treatment | Febuxostat XR 80 mg | 26.6 | percentage of participants | ||
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | Placebo | 0.6 | percentage of participants | ||
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | Febuxostat IR 40 mg | 40.3 | percentage of participants | ||
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | Febuxostat XR 40 mg | 48.2 | percentage of participants | ||
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | Febuxostat IR 80 mg | 57.7 | percentage of participants | ||
| Percentage of Participants With Serum Urate <6.0 mg/dL at Month 3 | Febuxostat XR 80 mg | 61.1 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02139046/results